Committees

The Corporate Administration and Transactions Committee reviews, approves and confirms matters in connection with the administration of the Company and its group’s business, and certain corporate transactions.

Its members include:

All GSK plc Board Directors
GLT members
Company Secretary

Terms of reference Corporate Administration and Transactions Committee (PDF - 150KB).

Chair: 

• Emma Walmsley

Members:

• Diana Conrad - Chief People Officer
• Julie Brown - Chief Financial Officer
• James Ford - SVP and Group General Counsel, Legal and Compliance
• Sally Jackson - Senior Vice President, Global Communications and CEO Office
• Luke Miels - Chief Commercial Officer
• Shobie Ramakrishnan - Chief Digital & Technology Officer
• David Redfern - President, Corporate Development
• Phil Thomson - President, Global Affairs
• Regis Simard - President, Global Supply Chain
• Deborah Waterhouse - CEO, ViiV Healthcare
• Tony Wood - Chief Scientific Officer

Secretary:

• SVP, Global Communications and CEO Office

Frequency of meetings:

• The GLT meets 11 times per year.

The GLT assists the CEO in the executive management of the company.

Membership

The Risk Oversight and Compliance Council (ROCC) is co-chaired by the  Group General Counsel, and the Chief Financial Officer, and includes at least three members of the GSK Leadership Team (GLT) appointed by the CEO. Other members include the Company Secretary and the Head of Audit & Assurance.

Purpose

The ROCC assists the Audit & Risk Committee in its review of activities and helps to ensure that effective internal controls are implemented for all significant risks. The establishment of the ROCC was approved by our Board, guided by the Corporate Compliance Officer.

Reporting line

In accordance with its role, the Audit & Risk Committee reviews information and reports from the ROCC and in turn reports to our Board on these matters.

Responsibility

The ROCC is responsible for carrying out the following tasks:

• Ensure a robust process exists for the business to identify significant risks to which GSK is exposed
• Ensure Enterprise Risk Strategies are fit for purpose, root causes of significant incidents and adverse audit outcomes are understood, and effective corrective and preventive actions are implemented
• Escalate issues, critical audit findings or risks to the GSK Leadership Team and Audit & Risk Committee that require action or where significant exposure to GSK may exist
• Ensure effective communication and reporting of important risk and control information between other key risk committees, GSK Leadership Team and Audit & Risk Committee
• Deliver visible leadership in promoting GSK’s values as part of risk management.

Chair:

• Company Secretary

Members:

• Group Financial Controller
• President, Global Affairs
• SVP, Corporate Affairs
• SVP, Head of Investor Relations
• VP & Head of Legal, Business Development and Corporate (UK)
• Assistant General Counsel, Litigation, Employment, Digital & Privacy (US)
• SVP Science and Innovation Communications
• Investor Relations Director (US)

Secretary:

• Assistant Company Secretary

In attendance:

Representatives from:

• Our external auditors
• Our external legal advisers UK and US
• Our brokers
• Internal experts (including Head of Global Finance Reporting & Analysis)

The Disclosure Committee was established by the CEO and the CFO and has responsibility for considering the materiality of information (information that may affect our stock price), and determining on a timely basis the disclosure of this information. The committee meets as necessary.

Download the Disclosure Committee's terms of reference (PDF - 299KB)